Showing 9941-9950 of 18550 results for "".
- Cancer Immunotherapy: Engineered Super-Strong Antibodies for Immune System Boosthttps://reachmd.com/news/cancer-immunotherapy-engineered-super-strong-antibodies-for-immune-system-boost/2474425/Major advancements in cancer immunotherapy have introduced engineered antibodies that remarkably boost immune defense mechanisms in cancer patients. This groundbreaking strategy complements existing treatment methods, aiming to optimize patient outcome
- Postpartum Care and Intensive Support for Parents of Premature Infantshttps://reachmd.com/news/postpartum-care-and-intensive-support-for-parents-of-premature-infants/2474333/The arrival of a premature infant introduces a cascade of medical, emotional, and logistical challenges, demanding not only specialized neonatal care but also comprehensive, individualized postpartum support. As neonatal intensive care units (NICUs) continue to adv
- Pulmonary Fibrosis: Evaluating Cancer Drug Repurposing for IPFhttps://reachmd.com/news/pulmonary-fibrosis-evaluating-cancer-drug-repurposing-for-ipf/2474377/In the relentless search for effective therapies against idiopathic pulmonary fibrosis (IPF), a devastating lung disease with few treatment options, researchers are increasingly turning to an unexpected source: cancer drugs. Recent investigations from Tulane Univer
- Exploring Genetic Pathways and Immune Mechanisms in Colorectal Cancerhttps://reachmd.com/news/the-role-of-immune-related-gene-expression-in-colorectal-cancer-risk/2474419/Cutting-edge research employing Mendelian randomization analysis has uncovered significant associations between immune-related gene expression and colorectal cancer (CRC) risk. These findings offer new perspectives on the genetic mechanisms underlying CRC
- Duchenne Muscular Dystrophy: Evaluating Existing Treatments for Inflammation Controlhttps://reachmd.com/news/duchenne-muscular-dystrophy-evaluating-existing-treatments-for-inflammation-control/2474408/Duchenne muscular dystrophy is a genetic disorder that results in progressive muscle weakness and persistent inflammation. This chronic inflammatory state not only accelerates muscle deterioration but also contributes to a more complicated disease trajectory. <
- Oxidative Stress and Its Impact on Hypertension and Aortic Aneurysmshttps://reachmd.com/news/oxidative-stress-and-its-impact-on-hypertension-and-aortic-aneurysms/2474407/Oxidative Stress and Its Impact on Hypertension and Aortic Aneurysms Uncovering the Cardiovascular Consequences of Oxidative Stress Recent research illuminates the significant role of reactive oxygen species in causing cellular damage
- Metabolites and Diet Assessment: Integrating Blood Plasma Analysishttps://reachmd.com/news/metabolites-and-diet-assessment-integrating-blood-plasma-analysis/2474406/Recent advancements in metabolomics are revolutionizing dietary assessment by combining blood plasma metabolite analysis with traditional self-reporting methods, effectively addressing data inaccuracies and enhancing nutritional evaluations. Li
- Ageing and Dementia Risk: The Impact of Biological Versus Chronological Agehttps://reachmd.com/news/ageing-and-dementia-risk-the-impact-of-biological-versus-chronological-age/2474405/Recent studies underscore a critical link between the divergence of biological and chronological age and dementia risk. Individuals whose biological age surpasses their actual years may face increased vulnerability, emphasizing the importance of advanc
- Environmental Factors: Impact of Extreme Temperatures on Dietary Patternshttps://reachmd.com/news/environmental-factors-impact-of-extreme-temperatures-on-dietary-patterns/2474414/New research is revealing an unexpected connection between environmental extremes and dietary behavior. In a series of global nutrition studies, brief exposure to extreme temperatures—both hot and cold—was found to significantly alter food choices, prompting an inc
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://reachmd.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.